Department of Biological & Technological Research, San Raffaele Scientific Institute, Milan, Italy.
Cytotechnology. 1996 Jan;22(1-3):197-203. doi: 10.1007/BF00353939.
The CHO cell line has achieved considerable commercial importance as a vehicle for the production of human therapeutic proteins, but is known to lack a functional copy of the gene coding for α2,6-sialyltransferase (EC 2.4.99.1). The cDNA for rat α2,6-ST was expressed in a recombinant CHO cell line making interferon-γ, using a novel in vitro amplification vector. The enzyme was expressed efficiently, and resulted in up to 60% of the total sialic acids on interferon-γ being linked in the α2,6-conformation. This sialic acid linkage distribution was more akin to that seen in natural human glycoproteins. In the most successful cell clones, expression of α2,6-sialyltransferase improved the overall level of sialylation by up to 56%, and had no adverse effects on cell growth, IFN-γ productivity or other aspects of IFN-γ glycosylation. These experiments demonstrate how the glycosylation machinery of rodent cells can be genetically manipulated to replicate human tissues.
CHO 细胞系作为生产人类治疗性蛋白的载体已经取得了相当大的商业重要性,但已知其缺乏编码α2,6-唾液酸转移酶(EC 2.4.99.1)的基因的功能副本。使用新型体外扩增载体,在重组 CHO 细胞系中表达编码大鼠α2,6-ST 的 cDNA,该细胞系可产生干扰素-γ。该酶表达效率高,导致干扰素-γ上多达 60%的总唾液酸以α2,6-构型连接。这种唾液酸连接分布更类似于天然人糖蛋白中观察到的分布。在最成功的细胞克隆中,α2,6-唾液酸转移酶的表达将唾液酸化的总体水平提高了多达 56%,并且对细胞生长、IFN-γ 生产力或 IFN-γ 糖基化的其他方面没有不利影响。这些实验证明了如何对啮齿动物细胞的糖基化机制进行遗传操作以复制人类组织。